• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.

作者信息

Stefka A T, Park J-H, Matsuo Y, Chung S, Nakamura Y, Jakubowiak A J, Rosebeck S

机构信息

Department of Medicine, University of Chicago, Chicago, IL, USA.

OncoTherapy Science, Inc., Kawasaki, Japan.

出版信息

Blood Cancer J. 2016 Aug 19;6(8):e460. doi: 10.1038/bcj.2016.71.

DOI:10.1038/bcj.2016.71
PMID:27540718
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5022182/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/010b/5022182/083d97e0f16e/bcj201671f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/010b/5022182/335ee334a398/bcj201671f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/010b/5022182/083d97e0f16e/bcj201671f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/010b/5022182/335ee334a398/bcj201671f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/010b/5022182/083d97e0f16e/bcj201671f2.jpg

相似文献

1
Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.MELK抑制剂OTS167的抗骨髓瘤活性：对耐药骨髓瘤细胞及恶性浆细胞假定骨髓瘤干细胞补充的影响
Blood Cancer J. 2016 Aug 19;6(8):e460. doi: 10.1038/bcj.2016.71.
2
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease.母体胚胎亮氨酸拉链激酶抑制剂 OTSSP167 在多发性骨髓瘤骨病中具有临床前活性。
Haematologica. 2018 Aug;103(8):1359-1368. doi: 10.3324/haematol.2017.185397. Epub 2018 May 10.
3
Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.通过 TGFβ 抑制来阻断骨髓成纤维细胞中的促生存自噬作用，可克服多发性骨髓瘤患者对硼替佐米的耐药性。
Leukemia. 2016 Mar;30(3):640-8. doi: 10.1038/leu.2015.289. Epub 2015 Oct 21.
4
Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.与MELK抑制剂抗肿瘤活性相关生物标志物的临床前评估
Oncotarget. 2016 Apr 5;7(14):18171-82. doi: 10.18632/oncotarget.7685.
5
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.克隆性多发性骨髓瘤祖细胞、干细胞特性及耐药性。
Cancer Res. 2008 Jan 1;68(1):190-7. doi: 10.1158/0008-5472.CAN-07-3096.
6
Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.评估多种靶向药物对多发性骨髓瘤患者浆细胞和假定肿瘤干细胞的体外作用。
Oncotarget. 2016 Oct 4;7(40):65627-65642. doi: 10.18632/oncotarget.11593.
7
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.将托法替尼重新用于骨髓瘤治疗以逆转骨髓微环境的促生长作用。
Haematologica. 2018 Jul;103(7):1218-1228. doi: 10.3324/haematol.2017.174482. Epub 2018 Apr 5.
8
The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.新型泛 PIM 激酶抑制剂 PIM447 具有双重抗骨髓瘤和护骨作用，并与当前标准治疗方案具有强大的协同作用。
Clin Cancer Res. 2017 Jan 1;23(1):225-238. doi: 10.1158/1078-0432.CCR-16-0230. Epub 2016 Jul 20.
9
Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.多发性骨髓瘤中 Polo 样激酶 1 的表达、不良预后意义和治疗性小分子抑制作用。
Leuk Res. 2011 Dec;35(12):1637-43. doi: 10.1016/j.leukres.2011.07.016. Epub 2011 Aug 3.
10
Targeting the Pim kinases in multiple myeloma.靶向多发性骨髓瘤中的Pim激酶。
Blood Cancer J. 2015 Jul 17;5(7):e325. doi: 10.1038/bcj.2015.46.

引用本文的文献

1
MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways.MELK抑制通过阻断AKT和FOXM1信号通路有效抑制胶质母细胞瘤和癌症干细胞样细胞的生长。
Front Oncol. 2021 Jan 14;10:608082. doi: 10.3389/fonc.2020.608082. eCollection 2020.
2
Enigmatic MELK: The controversy surrounding its complex role in cancer.神秘的 MELK：其在癌症中复杂作用引发的争议。
J Biol Chem. 2020 Jun 12;295(24):8195-8203. doi: 10.1074/jbc.REV120.013433. Epub 2020 Apr 29.
3
Phillygenin, a MELK Inhibitor, Inhibits Cell Survival and Epithelial-Mesenchymal Transition in Pancreatic Cancer Cells.

本文引用的文献

1
Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.与MELK抑制剂抗肿瘤活性相关生物标志物的临床前评估
Oncotarget. 2016 Apr 5;7(14):18171-82. doi: 10.18632/oncotarget.7685.
2
Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.通过卡非佐米和塞利尼索对胱天蛋白酶-10依赖性凋亡的新型细胞内激活实现协同性骨髓瘤细胞死亡。
Mol Cancer Ther. 2016 Jan;15(1):60-71. doi: 10.1158/1535-7163.MCT-15-0488. Epub 2015 Dec 4.
3
MELK-a conserved kinase: functions, signaling, cancer, and controversy.
知母皂苷元，一种MELK抑制剂，可抑制胰腺癌细胞的细胞存活和上皮-间质转化。
Onco Targets Ther. 2020 Apr 3;13:2833-2842. doi: 10.2147/OTT.S238958. eCollection 2020.
4
Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1.突变型P53通过解除野生型P53对FOXM1的依赖性抑制作用来诱导MELK表达。
NPJ Breast Cancer. 2020 Jan 3;6:2. doi: 10.1038/s41523-019-0143-5. eCollection 2020.
5
Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma.抑制MELK原癌基因作为肝内胆管癌的创新治疗方法。
Medicina (Kaunas). 2019 Dec 18;56(1):1. doi: 10.3390/medicina56010001.
6
Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway.MELK 抑制通过 ATM/CHK2/p53 通路诱导 G1/S 细胞周期停滞，从而在膀胱癌中产生潜在的抗肿瘤作用。
J Cell Mol Med. 2020 Jan;24(2):1804-1821. doi: 10.1111/jcmm.14878. Epub 2019 Dec 10.
7
Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.母系胚胎亮氨酸拉链激酶是弥漫性大 B 细胞淋巴瘤和套细胞淋巴瘤的一个新靶点。
Blood Cancer J. 2019 Nov 18;9(12):87. doi: 10.1038/s41408-019-0249-x.
8
Kinome expression profiling to target new therapeutic avenues in multiple myeloma.对激酶组进行表达谱分析，以寻找多发性骨髓瘤的新治疗途径。
Haematologica. 2020 Mar;105(3):784-795. doi: 10.3324/haematol.2018.208306. Epub 2019 Jul 9.
9
Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.母系胚胎亮氨酸拉链激酶（MELK）：神经母细胞瘤的一个潜在治疗靶点。
Mol Cancer Ther. 2019 Mar;18(3):507-516. doi: 10.1158/1535-7163.MCT-18-0819. Epub 2019 Jan 23.
10
Challenges in validating candidate therapeutic targets in cancer.癌症候选治疗靶点验证中的挑战。
Elife. 2018 Feb 8;7:e32402. doi: 10.7554/eLife.32402.
MELK——一种保守激酶：功能、信号传导、癌症及争议
Clin Transl Med. 2015 Mar 7;4:11. doi: 10.1186/s40169-014-0045-y. eCollection 2015.
4
Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.从基础到临床，再回到基础：理解生物学以攻克疾病——多发性骨髓瘤。
CA Cancer J Clin. 2014 Nov-Dec;64(6):422-44. doi: 10.3322/caac.21252. Epub 2014 Sep 29.
5
Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1.通过多能干细胞荧光染料 CDy1 鉴定 ABCB1（P-糖蛋白）阳性的卡非佐米耐药骨髓瘤亚群。
Am J Hematol. 2013 Apr;88(4):265-72. doi: 10.1002/ajh.23387. Epub 2013 Mar 8.
6
MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.MELK 依赖性 FOXM1 磷酸化对于神经胶质瘤干细胞的增殖是必需的。
Stem Cells. 2013 Jun;31(6):1051-63. doi: 10.1002/stem.1358.
7
Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.一种口服给药的靶向MELK的抑制剂的研发，该抑制剂可抑制多种类型人类癌症的生长。
Oncotarget. 2012 Dec;3(12):1629-40. doi: 10.18632/oncotarget.790.
8
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.克隆性多发性骨髓瘤祖细胞、干细胞特性及耐药性。
Cancer Res. 2008 Jan 1;68(1):190-7. doi: 10.1158/0008-5472.CAN-07-3096.
9
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.通过基因表达谱分析对超二倍体多发性骨髓瘤进行分子剖析。
Cancer Res. 2007 Apr 1;67(7):2982-9. doi: 10.1158/0008-5472.CAN-06-4046.
10
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.一种经过验证的高危多发性骨髓瘤基因表达模型是由定位于1号染色体上的基因表达失调所定义的。
Blood. 2007 Mar 15;109(6):2276-84. doi: 10.1182/blood-2006-07-038430. Epub 2006 Nov 14.